Donanemab Slows Alzheimer's Progression in Topline Data
The anti-amyloid hopeful markedly reduced brain amyloid plaque and significantly slowed cognitive and functional decline in adults with early AD in the TRAILBLAZER-ALZ 2 trial.
Source: medscape.com